NCT05347212 2026-04-15
Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
Clinical Trials
27 trialsNCT05283226 2026-01-23
Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy
NATCO Pharma Ltd.
Phase 2 Recruiting
NCT05977998 2025-11-19
A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06969534 2025-05-15
Safety and Efficacy of Pucotenlimab in pLECC
Sun Yat-sen University
Phase 2 Recruiting
NCT04050436 2025-01-27
CERPASS
Replimune Inc.
Phase 2 Active not recruiting
NCT05917158 2025-01-22
1
Jinling Hospital, China
Phase 2 Recruiting
NCT03396471 2024-04-18
Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary
Hoosier Cancer Research Network
Phase 2 Terminated
NCT06112041 2023-11-01
The Prospective Clinical Study of Precision PRaG Therapy in Elderly Patients With Advanced Solid Malignant Tumors (PRaG9.0)
Second Affiliated Hospital of Soochow University
Phase 2 Not yet recruiting
NCT02412670 2023-07-10
Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00176267 2023-06-01
Paclitaxel, Carboplatin And Low Dose Radiation As Induction Therapy In Locally Advanced Head And Neck Cancer
University of Kentucky
Phase 2 Completed
NCT00176254 2023-05-16
Paclitaxel, Carboplatin and Radiotherapy as Induction Therapy in Locally Advanced Head and Neck Cancer
University of Kentucky
Phase 2 Completed
NCT02213133 2023-01-26
STARRS
Karyopharm Therapeutics Inc
Phase 2 Terminated
NCT04985825 2022-09-13
I-PACE
Centessa Pharmaceuticals plc
Phase 2 Withdrawn
NCT02920476 2022-06-23
UF-STO-LUNG-003
University of Florida
Phase 2 Completed
NCT05115500 2021-11-10
ADC Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of HER-2 Positive Advanced Solid Tumors(PRaG3.0)
Second Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT02883556 2021-01-13
CARSKIN
Assistance Publique - Hôpitaux de Paris
Phase 2 Completed
NCT04698213 2021-01-06
TIDE-A
Consorzio Oncotech
Phase 2 Unknown
NCT00818441 2019-01-08
Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung
Pfizer
Phase 2 Completed
NCT00737243 2016-08-17
Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00998192 2016-03-31
A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung
Oncolytics Biotech
Phase 2 Completed
NCT01301612 2014-07-14
Study of Nimotuzumab, Radiation Therapy and Cisplatin Versus Radiation Therapy and Cisplatin for Treatment of Stage IB e IVA UCC(CORUS)
Eurofarma Laboratorios S.A.
Phase 2 Withdrawn
NCT01097083 2014-01-14
Coriolus Versicolor as Palliative Therapy Compared to Placebo in Patients With Child-Pugh C Unresectable Hepatocellular Carcinoma
National University Hospital, Singapore
Phase 2 Terminated
NCT00988741 2013-02-28
Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 2 Completed
NCT00799084 2011-12-07
ATSM
Michigan State University
Phase 2 Completed
NCT01070537 2010-02-18
INVIBO
Centre Leon Berard
Phase 2 Completed
NCT00137423 2009-09-30
Study Of SU011248 (Sunitinib) Given In A Continuous Daily Regimen In Patients With Advanced Renal Cell Cancer
Pfizer
Phase 2 Completed
NCT00894569 2009-05-14
PACET-CUP
Heidelberg University
Phase 2 Unknown